The National Institute of Allergy and Infectious Diseases (NIAID) had its origins in the earliest days of the Public Health Service. In 1948, the Rocky Mountain Laboratory and the Biologics Control Laboratory, both dating to 1902, joined the Division of Infectious Diseases and the Division of Tropical Diseases of the National Institutes of Health to form the National Microbiological Institute. Six years later, Congress gave the Institute its present name to reflect the inclusion of allergy and immunology research. Today, NIAID provides the major support for scientists conducting research aimed at developing better ways to diagnose, treat and prevent the many infectious, immunologic and allergic diseases that afflict people worldwide.
NIAID is composed of four extramural divisions: the Division of AIDS, the Division of Allergy, Immunology and Transplantation, the Division of Microbiology and Infectious Diseases, and the Division of Extramural Activities. In addition, NIAID scientists conduct intramural research in laboratories located in Bethesda, Rockville and Frederick, Maryland, and in Hamilton, Montana.
Following is a brief description of the major areas of investigation.
Other areas of research include fungal diseases, hospital-associated infections, chronic fatigue syndrome, respiratory diseases, and antiviral and antimicrobial drug development.
Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
NIAID welcomes your comments and suggestions. Please send them to: email@example.com
NIAID Office of Communications Building 31, Room 7A-50
31 Center Drive MSC 2520
Bethesda, MD 20892-2520
United States of America
Categories Covered:HIV Epidemiology, HIV Prevention Methods, HIV Treatments in Development, PrEP (HIV Pre-Exposure Prophylaxis), Managing Primary/Acute HIV Infection, Managing People Newly Diagnosed With HIV, HIV Care Continuum, HIV Treatment Strategies, HIV Basic Science and Pathogenesis, Adverse Events, Comorbidities, and HIV, HIV Policy and Advocacy, First-Line HIV Treatment, Tenofovir Disoproxil Fumarate (Viread), Abacavir (Ziagen), Nevirapine (Viramune), Lopinavir/Ritonavir (Kaletra), HIV Testing, Pregnancy, Childbirth, and HIV, HIV Education and Risk Management
Writing in JAMA, officials from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) review the scientific evidence underlying U=U and discuss the implications of widespread acceptance of the message.
At last week's HIV Research for Prevention (HIVR4P) conference in Madrid, scientists reported progress in numerous areas of HIV prevention research.
A durable end to the HIV/AIDS pandemic will require the development and widespread implementation of new and improved HIV prevention tools, according to NIAID Director Anthony S. Fauci, M.D.
Researchers are working to visualize and predict immune reconstitution syndrome (IRIS) in people with HIV in a new way -- with positron emission tomography (PET).
People living with HIV whose virus is completely, durably suppressed by treatment will not sexually transmit the virus to an HIV-negative partner, according to NIAID Director Anthony S. Fauci, M.D.
Why do we lack a cure for HIV infection, and what research is underway to help achieve that goal? A new video from NIAID provides answers.
A clinical trial of Kaposi's sarcoma treatments was ended early as interim data showed that participants who were treated with paclitaxel plus ART had better tumor outcomes than participants who received the other treatment regimens.
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world.
Researchers report that the presence of plaque in the coronary arteries, a common risk factor for heart attacks, manifests itself differently in women living with HIV than in men.
NIAID researchers and scientists at the Uganda Virus Research Institute describe a case of HIV superinfection they were able to identify with unique precision.